No price history available.
Key financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SGDm | 568 | 724 | 823 | 708 | 752 | 765 | N/A | N/A |
| Operating profit | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SGDm | 66 | 84 | 143 | 90 | 62 | 71 | N/A | N/A |
| EPS reported | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Raffles Medical Group Ltd (RMG), a prominent Singapore-headquartered company, delivers integrated private healthcare services across Singapore, Greater China, Vietnam, Cambodia, and Japan. Its operations are structured into Healthcare Services, Hospital Services, and Investment Holdings segments. The group's flagship institution, Raffles Hospital, functions as a tertiary care facility, offering a broad spectrum of medical services. These include oncology, pediatrics and women's health, traditional Chinese medicine, counseling, dental care, dialysis, diabetes and endocrinology, ENT, ophthalmology, fertility treatments, cardiology, internal medicine, neuroscience, pain management, rehabilitation, orthopedics, dermatological and aesthetic services, general surgery, nuclear medicine, and urology. Beyond the hospital, RMG provides emergency services, family medicine, comprehensive health screening, and a variety of multi-disciplinary specialist clinic services. Additionally, the company engages in the trade of pharmaceutical and nutraceutical products, and diagnostic equipment. It also offers advisory and consultancy services, develops IT solutions, and undertakes research and experimental development in biotechnology, life sciences, and medical science. The company was founded in 1976.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Raffles Medical Group Ltd (RMG), a prominent Singapore-headquartered company, delivers integrated private healthcare services across Singapore, Greater China, Vietnam, Cambodia, and Japan. Its operations are structured into Healthcare Services, Hospital Services, and Investment Holdings segments. The group's flagship institution, Raffles Hospital, functions as a tertiary care facility, offering a broad spectrum of medical services. These include oncology, pediatrics and women's health, traditional Chinese medicine, counseling, dental care, dialysis, diabetes and endocrinology, ENT, ophthalmology, fertility treatments, cardiology, internal medicine, neuroscience, pain management, rehabilitation, orthopedics, dermatological and aesthetic services, general surgery, nuclear medicine, and urology. Beyond the hospital, RMG provides emergency services, family medicine, comprehensive health screening, and a variety of multi-disciplinary specialist clinic services. Additionally, the company engages in the trade of pharmaceutical and nutraceutical products, and diagnostic equipment. It also offers advisory and consultancy services, develops IT solutions, and undertakes research and experimental development in biotechnology, life sciences, and medical science. The company was founded in 1976.